These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1612 related articles for article (PubMed ID: 36248822)

  • 21. Cuproptosis-Related LncRNA Signature for Predicting Prognosis of Hepatocellular Carcinoma: A Comprehensive Analysis.
    Chen Q; Sun T; Wang G; Zhang M; Zhu Y; Shi X; Ding Z
    Dis Markers; 2022; 2022():3265212. PubMed ID: 36452343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
    Gao S; Zhang L; Wang H
    Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
    Jiang H; Chen H; Wang Y; Qian Y
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and validation of a novel cuproptosis-related genes signature associated with prognosis, clinical implications and immunotherapy of hepatocellular carcinoma.
    He F; Zeng P; Ma S; Yang X; Liu H; Liu Q; Zhou Y; Zhu H
    Front Pharmacol; 2023; 14():1088993. PubMed ID: 36843949
    [No Abstract]   [Full Text] [Related]  

  • 25. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
    Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
    World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.
    Wang X; Chen D; Shi Y; Luo J; Zhang Y; Yuan X; Zhang C; Shu H; Yu W; Tian J
    Front Immunol; 2023; 14():1123231. PubMed ID: 37153542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma.
    Zhu J; Huang Q; Liu S; Peng X; Xue J; Feng T; Huang W; Chen Z; Lai K; Ji Y; Wang M; Yuan R
    Front Immunol; 2022; 13():856186. PubMed ID: 35479067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction and systematic evaluation of a machine learning-based cuproptosis-related lncRNA score signature to predict the response to immunotherapy in hepatocellular carcinoma.
    Lu D; Liao J; Cheng H; Ma Q; Wu F; Xie F; He Y
    Front Immunol; 2023; 14():1097075. PubMed ID: 36761763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma.
    Zhang L; Xu J; Chu X; Zhang H; Yao X; Zhang J; Guo Y
    BMC Bioinformatics; 2022 Nov; 23(1):485. PubMed ID: 36384423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and development of a novel risk model based on cuproptosis-associated RNA methylation regulators for predicting prognosis and characterizing immune status in hepatocellular carcinoma.
    Li D; Shi Z; Liu X; Jin S; Chen P; Zhang Y; Chen G; Fan X; Yang J; Lin H
    Hepatol Int; 2023 Feb; 17(1):112-130. PubMed ID: 36598701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of PANoptosis-related subtypes, construction of a prognosis signature, and tumor microenvironment landscape of hepatocellular carcinoma using bioinformatic analysis and experimental verification.
    Ouyang G; Li Q; Wei Y; Dai W; Deng H; Liu Y; Li J; Li M; Luo S; Li S; Liang Y; Pan G; Yang J; Gan T
    Front Immunol; 2024; 15():1323199. PubMed ID: 38742112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
    Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX
    Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
    BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel cuproptosis-related prognostic lncRNA signature for predicting immune and drug therapy response in hepatocellular carcinoma.
    Chen S; Liu P; Zhao L; Han P; Liu J; Yang H; Li J
    Front Immunol; 2022; 13():954653. PubMed ID: 36189204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
    Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P
    Front Immunol; 2022; 13():998236. PubMed ID: 36110851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cuproptosis-related signature for clinical prognosis and immunotherapy sensitivity in hepatocellular carcinoma.
    Xu S; Dong K; Gao R; Yang Y; Zhou Y; Luo C; Chen W; Liu SM
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):12249-12263. PubMed ID: 37434092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct cuproptosis patterns in hepatocellular carcinoma patients correlate with unique immune microenvironment characteristics and cell-cell communication, contributing to varied overall survival outcomes.
    Wang Y; Mang X; Guo X; Pu J
    Front Immunol; 2024; 15():1379690. PubMed ID: 38868777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ferroptosis and cuproptosis prognostic signature for prediction of prognosis, immunotherapy and drug sensitivity in hepatocellular carcinoma: development and validation based on TCGA and ICGC databases.
    Ma Q; Hui Y; Huang BR; Yang BF; Li JX; Fan TT; Gao XC; Ma DY; Chen WF; Pei ZX
    Transl Cancer Res; 2023 Jan; 12(1):46-64. PubMed ID: 36760376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
    Wang L; Wang L; He P
    Front Genet; 2022; 13():1064432. PubMed ID: 36568383
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 81.